PlantForm Corporation is a Canadian biotech company with a low-cost, proprietary manufacturing platform for a wide range of plant-made pharmaceuticals, including monoclonal antibodies, therapeutic proteins and vaccines for the treatment of cancer, ricin exposure, HIV/AIDS, Ebola virus and other life-threatening conditions.
The company’s vivoXPRESS® technology uses genetically modified tobacco plants to ‘grow’ biopharmaceuticals in fully contained greenhouse environments. Our plant-based technology delivers high drug expression levels and fully mammalian glycosylation (to eliminate the risk of an unwanted immune system reaction). vivoXPRESS® also provides the following key advantages compared to other fermentation systems for biologic drug production (e.g., mammalian cell culture):
rapid drug development & production timelines
versatile manufacturing platform (for new product development)
unlimited scale-up capability, and
low manufacturing costs (approximately one-tenth of mammalian-cell systems)
See our vivoXPRESS® manufacturing platform diagram.
The PlantForm research team continues to advance the vivoXPRESS® platform, which originated at the University of Guelph through the work of Dr. J. Christopher Hall, a PlantForm founder and the company’s Chief Scientific Officer. All relevant intellectual property is protected by six families of patent filings, with three patents issued to date.
PlantForm’s pipeline features both innovator and biosimilar products, including:
biosimilar trastuzumab, a plant-produced version of the breast cancer drug Herceptin®, which had C$8.6 billion in sales in 2015
biosimilar versions of two additional biologic cancer drugs that had combined annual global sales of up to $12.3 billion in 2015
an innovator antibody for treatment of ricin exposure
innovator antibodies for HIV/AIDS, funded by the Government of Canada and the Bill & Melinda Gates Foundation
innovator antibodies for treatment of Ebola virus (Sudan strain), with financial support from the National Research Council of Canada Industrial Research Assistance Program (NRC-IRAP) and in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID)
recombinant butyrylcholinesterase (BuChE), an enzyme used as preventative medicine for people vulnerable to attack by nerve agents, organophosphates or other stimulants.
PlantPraxis is a joint venture formed in 2014 by PlantForm and PharmaPraxis of Brazil to develop, manufacture and commercialize biosimilar and/or biobetter versions of six key biopharmaceuticals for the Brazilian market, using PlantForm’s low-cost manufacturing system.
PlantForm is interested in establishing partnerships with other companies to develop additional targeted biosimilar and innovator drugs.
PlantForm is committed to producing high-value biopharmaceuticals in an environmentally and socially responsible manner to improve the quality of life and survival of patients with cancer and other critical illnesses.